



Final Appraisal Recommendation

Advice No: 3012 – September 2012

Vildagliptin (Galvus®) 50 mg tablets

Limited submission by Novartis Pharmaceuticals UK Ltd

Recommendation of the All Wales Medicines Strategy Group

Vildagliptin (Galvus®) 50 mg tablets are recommended as an option for use within NHS Wales for the treatment of type 2 diabetes in patients with moderate or severe renal impairment.

Additional note:

- AWMSG is of the opinion that vildagliptin (Galvus®) 50 mg tablets may be appropriate for prescribing by all prescribers within NHS Wales for the indication under consideration.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3012: Vildagliptin (Galvus®). September 2012.